Author
@BPharmCatalyst BPharmCatalyst
High-volume biotech catalyst news feed: FDA, trial readouts, M&A, financings, all tickered.
Aggregate and relay real-time clinical-stage biopharma event
trader score
·
hit rate
·
mean α
·
signals 14d
41
Grade = how their written analysis reads (A best). Trader score = how their last-20 timestamped calls performed vs SPY.
Their picks, scored
Not yet in the scored-bets universe (fewer than 20 scoreable calls). Their last-14d mentions, direction-adjusted, have moved +5.5% since posting (mean over 10 mentions with price data).
Recent signals15receipts included
| date (PT) | ticker | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|---|
| 2026-08-28 | TAK | @BPharmCatalyst | +0.50 | Reports FDA approval of MIMRYLO for polycythemia vera | · | tweet ↗ |
| 2026-08-28 | PTGX | @BPharmCatalyst | +0.50 | Reports FDA approval of MIMRYLO for polycythemia vera | · | tweet ↗ |
| 2026-08-28 | TEVA | @BPharmCatalyst | +0.10 | BTAI entered Chapter 11 and named Teva stalking-horse bidder for nearly all assets | — | tweet ↗ |
| 2026-08-28 | BTAI | @BPharmCatalyst | -0.75 | BTAI entered Chapter 11 and named Teva stalking-horse bidder for nearly all assets | · | tweet ↗ |
| 2026-08-28 | ABEO | @BPharmCatalyst | +0.00 | Weekly biotech watchlist highlights upcoming quarterly catalysts | · | tweet ↗ |
| 2026-08-28 | TLX | @BPharmCatalyst | +0.00 | Weekly biotech watchlist highlights upcoming quarterly catalysts | · | tweet ↗ |
| 2026-08-28 | GPCR | @BPharmCatalyst | +0.00 | Weekly biotech watchlist highlights upcoming quarterly catalysts | — | tweet ↗ |
| 2026-08-28 | SRRK | @BPharmCatalyst | +0.00 | Weekly biotech watchlist highlights upcoming quarterly catalysts | · | tweet ↗ |
| 2026-08-28 | KOD | @BPharmCatalyst | +0.00 | Weekly biotech watchlist highlights upcoming quarterly catalysts | · | tweet ↗ |
| 2026-08-28 | PHVS | @BPharmCatalyst | +0.00 | Weekly biotech watchlist highlights upcoming quarterly catalysts | · | tweet ↗ |
| 2026-08-28 | QNRX | @BPharmCatalyst | +0.55 | Reports encouraging Phase 2/3 interim data and financing of up to $50M | · | tweet ↗ |
| 2026-08-27 | GILD | @BPharmCatalyst | +0.50 | FDA approved Gilead's Bixlenvo once-daily HIV regimen. | -2.1% | tweet ↗ |
| 2026-08-27 | CELU | @BPharmCatalyst | +0.65 | CELU established a U.S. manufacturing partnership estimated above $300M in purchase orders. | · | tweet ↗ |
| 2026-08-27 | MRNA | @BPharmCatalyst | +0.50 | FDA approved Moderna's updated 2026-2027 COVID vaccine formulas. | -3.3% | tweet ↗ |
| 2026-08-27 | ROIV | @BPharmCatalyst | +0.55 | FDA approved Priovant's LISRAYA as the first targeted dermatomyositis therapy. | · | tweet ↗ |
Grade is our human read-worthiness rating; trader score is a rolling 20-bet hit-rate/alpha composite — different things, often disagreeing. “Since then” is direction-unaware in the table; the summary line above adjusts for which way they leaned.